Covid19CALIPNCT04813731
COVID-19 And Lingering Symptoms In Primary Care Patients
An observational study of Covid19 and Symptoms and Signs, run by Katarina Hedin at 13 sites in 11 countries.
Trial summary
The ongoing corona virus disease 2019 (COVID-19) is a viral acute respiratory tract infection caused by server acute respiratory syndrom coronavirus typ 2 (SARS-CoV-2). The signs and symptom of SARS-CoV-2 infection vary and most people with COVID-19 experience illness of mild or moderate severity and recover with… Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Covid19, Symptoms and Signs
- How many people
- 300 participants
- Where
- 13 sitesin 11 countries
- Study dates
- 12 Dec 2020to 30 Jun 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Adult patients over all age categories with laboratory confirmed SARS-CoV-2 infection and symptoms consistent with COVID-19
Who may be able to join
- Confirmed SARS-CoV-2 infection, either by polymeras chain reaction (PCR), or by antigen testing (if authorized/recommended/used by national/local governments)
- Symptoms consistent with mild to moderate COVID-19
- Maximum of 2 weeks since positive SARS-CoV-2 test
- Aged 18 years and older
- Patient able and willing to comply with monthly phone calls.
Who cannot join
- Hospitalisation due to COVID-19
Trial locations and contacts
13 sites in 11 countries.
13 sites in 11 countries
Belgium2 sites
Centre for General Practice, Department of Family Medicine & Population Health (FAMPOP), Faculty of Medicine and Health Sciences, University of Antwerp
Antwerp
the Academic Centre for General Practice (ACHG), Department of Public Health and Primary Care, KU Leuven
Leuven
Sweden2 sites
Wetterhälsan Primary Health Care Centre
Jönköping
Kärna Primary Health Care Centre
Linköping
France1 site
Département de Santé Publique, Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Nice, France
Nice
Germany1 site
Institut für Allgemeinmedizin Universitätsklinikum Würzburg Josef-Schneider-Str. 2/D7 97080 Würzburg
Würzburg
Italy1 site
Covid-19 primary care special unit Sassuolo, Azienda Unità Sanitaria locale di Modena, Modena, Italy
Modena
Netherlands1 site
Julius Center, University Medical Center Utrecht
Utrecht
About this study
The ongoing corona virus disease 2019 (COVID-19) is a viral acute respiratory tract infection caused by server acute respiratory syndrom coronavirus typ 2 (SARS-CoV-2). The signs and symptom of SARS-CoV-2 infection vary and most people with COVID-19 experience illness of mild or moderate severity and recover with symptomatic treatment outside of hospital. Studies have found that some people experience lingering/long-lasting symptoms and only a minority of patients were completely free from COVID-19 related symptoms after two months. About one third still had up to two residual symptoms and 55% had three or more. As far as we know no study on lingering symptoms has been published in patients after a mild or moderate infection managed in primary care settings. The aim of this study is to explore the course of disease over a one year period and describe lingering symptoms and their impact on well-being and daily activities in adult non-hospitalized patients with previous established COVID-19 infection.
- Conditions
- Covid19, Symptoms and Signs
- Medical subject headings
- COVID-19, Signs and Symptoms
What is being measured
The primary outcome is the main question the study is designed to answer.
Time to full recovery symptoms
Number of weeks until "back to normal"
Measured: through study completion, a maximum of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Mar 2021
- Study start12 Dec 2020
- Primary completion30 Jun 2022
- Study completion30 Jun 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Covid19Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 300 participants (actual)
Sponsor and investigators
- Lead sponsor
- Katarina Hedin
- Sponsor type
- Other government
- Collaborators
- Research Unit for General Practice in Aalborg, Utrecht University, National University of Ireland, Galway, Ireland, Region Jönköping County
- Responsible party
- Sponsor-investigator, Katarina Hedin, Region Jönköping County
- Investigators
- Katarina Hedin, Assoc Prof, Principal investigator, Region Jönköping County Sweden
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04813731
- Sponsor's protocol ID
- 2020-05448
- Acronym
- CALIP
- Status last verified
- Aug 2025
- First submitted
- 7 Mar 2021
- Last updated
- 4 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- COVID-19 And Lingering Symptoms In Primary Care Patients
- ClinicalTrials.gov ID
- NCT04813731
- Acronym / sponsor ID
- CALIP / 2020-05448
- Conditions
- Covid19, Symptoms and Signs
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 300 participants (actual)
- Lead sponsor
- Katarina HedinOther government
- Collaborators
- Research Unit for General Practice in Aalborg, Utrecht University, National University of Ireland, Galway, Ireland, Region Jönköping County
- Study start
- 12 Dec 2020 (actual)
- Primary completion
- 30 Jun 2022 (actual)
- Study completion
- 30 Jun 2022 (actual)
- First posted
- 24 Mar 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The ongoing corona virus disease 2019 (COVID-19) is a viral acute respiratory tract infection caused by server acute respiratory syndrom coronavirus typ 2 (SARS-CoV-2). The signs and symptom of SARS-CoV-2 infection vary and most people with COVID-19 experience illness of mild or moderate severity and recover with symptomatic treatment outside of hospital. Studies have found that some people experience lingering/long-lasting symptoms and only a minority of patients were completely free from COVID-19 related symptoms after two months. About one third still had up to two residual symptoms and 55% had three or more. As far as we know no study on lingering symptoms has been published in patients after a mild or moderate infection managed in primary care settings. The aim of this study is to explore the course of disease over a one year period and describe lingering symptoms and their impact on well-being and daily activities in adult non-hospitalized patients with previous established COVID-19 infection.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patients over all age categories with laboratory confirmed SARS-CoV-2 infection and symptoms consistent with COVID-19
Key inclusion criteria (5 listed)
- Confirmed SARS-CoV-2 infection, either by polymeras chain reaction (PCR), or by antigen testing (if authorized/recommended/used by national/local governments)
- Symptoms consistent with mild to moderate COVID-19
- Maximum of 2 weeks since positive SARS-CoV-2 test
- Aged 18 years and older
- Patient able and willing to comply with monthly phone calls.
Key exclusion criteria (1 listed)
- Hospitalisation due to COVID-19
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Time to full recovery symptoms
Time frame: through study completion, a maximum of 1 year
Number of weeks until "back to normal"
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Sep 2025.
- Individual participant dataSharing planned: No
Related trials for Covid19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Katarina Hedin, Assoc Prof principal investigator
Region Jönköping County Sweden
13 sites in 11 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Covid19 and Symptoms and Signs, run by Katarina Hedin at 13 sites in 11 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 13 sites in Belgium, Sweden, Denmark, France, Georgia and 6 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time to full recovery symptoms (time frame: through study completion, a maximum of 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Sep 2025.